Status:
COMPLETED
Impact of 100mL Lipid Emulsion for Intravenous for Suppression of Myocardial Glucose Metabolism in 18F-FDG PET/CT
Lead Sponsor:
Centre Hospitalier Princesse Grace
Conditions:
Metabolic Preparation
Myocardial Inflammation
Eligibility:
All Genders
18-99 years
Brief Summary
There is increasing evidence that \[18F\]-2-fluoro-2-deoxy-D-glucose (18F-FDG) PET/CT is useful in the identification and treatment of disease processes that involve cardiac inflammation and infection...
Detailed Description
Methodology : Group of 30 consecutive patients with cardiac FDG PET prescribed, prospectively enrolled, compared to a group with the last 30 patients referred for cardiac FDG PET in the nuclear medic...
Eligibility Criteria
Inclusion
- Patients with an FDG PET/CT prescribed to explore cardiac disease process
Exclusion
- renal insufficiency,
- uncompensated diabetes mellitus,
- pancreatitis,
- liver insufficiency,
- hypothyroidism
- metabolic disorders
- sepsis.
- soy protein allergy
Key Trial Info
Start Date :
April 7 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 6 2020
Estimated Enrollment :
51 Patients enrolled
Trial Details
Trial ID
NCT04437927
Start Date
April 7 2020
End Date
November 6 2020
Last Update
November 9 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Hospitalier Princesse Grace
Monaco, Monaco